66025
document
Failure of lithium to reduce period of neutropenia during induction therapy of acute myeloid leukemia . Fifty-four patients treated with daunorubicin , cytosine arabinoside and thioquanine for acute myeloid leukemia were randomly assigned to receive oral lithium carbonate 1200 mg daily or no lithium . The duration of neutropenia ( less than 0.5 x 10 ( 9 ) /L ) was similar between controls ( median 22.5 days ) and patients treated with lithium ( median 24 days ) . The number of remissions , relapse-free survival and survival were similar for the lithium treated and control groups of patients . There was no apparent clinical efficacy in the use of lithium to reduce the period of neutropenia in patients undergoing remission induction therapy for acute myeloid leukemia .
66026
Intervention_Physical
induction therapy
66027
Intervention_Pharmacological
daunorubicin
66028
Intervention_Pharmacological
cytosine arabinoside
66029
Intervention_Pharmacological
thioquanine
66030
Intervention_Pharmacological
oral lithium carbonate 1200 mg daily
66031
Intervention_Pharmacological
no lithium
66032
Intervention_Pharmacological
lithium
66033
Intervention_Pharmacological
lithium
66034
Intervention_Pharmacological
lithium
66035
Intervention_Physical
induction therapy
66036
Outcome_Physical
duration of neutropenia
66037
Outcome_Physical
number of remissions
66038
Outcome_Mortality
relapse-free survival
66039
Outcome_Mortality
survival
66040
Outcome_Other
clinical efficacy
66041
Participant_Condition
acute myeloid leukemia
66042
Participant_Sample-size
Fifty-four
66043
Participant_Condition
patients treated with daunorubicin , cytosine arabinoside and thioquanine for acute myeloid leukemia